Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome (BTX-URO-01)

This study has been terminated.
(Slow accrual.)
Sponsor:
Collaborator:
Allergan
Information provided by (Responsible Party):
Daniel Stephan Engeler, Cantonal Hospital of St. Gallen
ClinicalTrials.gov Identifier:
NCT00464373
First received: April 20, 2007
Last updated: January 31, 2014
Last verified: January 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2013
  Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)